Considering the mode of action for oxLDL-mediated TLR9 suppression, our studies could be explained by oxLDL induced interference with TLR-ligand interaction [15,42] and/or uncoupling of TLR signaling in pDCs, as has previously been reported for the dyslipidemia associated inhibition of murine CD8α− cDC activation [14]. The gene discussed is TLR9; the disease is metabolic syndrome.